BiotechTube
Allergopharma

Allergopharma

Reinbek, Germany· Est.
allergopharma.dermapharm.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Allergopharma is a long-established, private German biotech focused exclusively on allergen immunotherapy (AIT), operating as a subsidiary of the publicly traded Dermapharm Group. The company is commercial-stage, with a portfolio of standardized allergy extracts for both diagnosis and subcutaneous/sublingual immunotherapy, targeting a broad range of respiratory and insect venom allergies. Its strategy is built on deep expertise in allergology, manufacturing quality, and a holistic approach to allergy management within the supportive infrastructure of a larger pharmaceutical group.

AllergyImmunology

Technology Platform

Standardized allergen extract production for diagnosis and immunotherapy (SCIT/SLIT).

Opportunities

Growing global prevalence of allergic diseases and increasing patient/physician preference for causal immunotherapy over symptomatic treatment creates a expanding market.
Integration into Dermapharm Group provides channels for geographic expansion and cross-portfolio synergies within specialty pharma.

Risk Factors

Intense competition from other AIT specialists and large pharma, alongside price pressure in European healthcare systems.
Regulatory complexity for biological allergen extracts and the potential for pipeline setbacks in developing next-generation therapies.

Competitive Landscape

Allergopharma competes in the allergen immunotherapy space against global leaders like ALK-Abelló (Denmark) and Stallergenes Greer (US/France), as well as numerous regional players and generic extract manufacturers. Its key differentiators are its long-standing German heritage, focus on high-quality standardized extracts, and backing by the Dermapharm commercial network.

More companies in Small Molecule Drugs →More companies in Germany →